Therefore, fermentates SC212 and SC210 could be novel candidates for the management of UC and CD in humans due to their ability to reduce the secretion of pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, TNF-α, and IL-27 while increasing the production of anti-inflammatory cytokine IL-10. This evidence concerns the gene IL6 and Cowden disease.